VEGFA and colorectal carcinoma: However, in HCC (125, 126, 159, 164) and some CRC (167) and RCC (144) studies listed in tables S2 and S3, most of the patients were not treated with anti-VEGF treatment, suggesting that anti-VEGF–responsive tumors generally seem to be more sensitive to RASi.